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Abstract
Background: Women with PCOS have elevated levels of the harmful Advanced Glycation End Products (AGEs),
which are highly reactive molecules formed after glycation of lipids and proteins. Additionally, AGEs accumulate in
the ovaries of women with PCOS potentially contributing to the well-documented abnormal steroidogenesis and
folliculogenesis.
Main body: A systematic review of articles and abstracts available in PubMed was conducted and presented in a
systemic manner. This article reports changes in steroidogenic enzyme activity in granulosa and theca cells in PCOS
and PCOS-models. It also described the changes in AGEs and their receptors in the ovaries of women with PCOS
and presents the underlying mechanism(s) whereby AGEs could be responsible for the PCOS-related changes in
granulosa and theca cell function thus adversely impacting steroidogenesis and follicular development. AGEs are
associated with hyperandrogenism in PCOS possibly by altering the activity of various enzymes such as cholesterol
side-chain cleavage enzyme cytochrome P450, steroidogenic acute regulatory protein, 17α-hydroxylase, and 3β-
hydroxysteroid dehydrogenase. AGEs also affect luteinizing hormone receptor and anti-Mullerian hormone receptor
expression as well as their signaling pathways in granulosa cells.
Conclusions: A better understanding of how AGEs alter granulosa and theca cell function is likely to contribute
meaningfully to a conceptual framework whereby new interventions to prevent and/or treat ovarian dysfunction in
PCOS can ultimately be developed.
Keywords: Advanced glycation end products (AGEs), RAGE, PCOS, Steroidogenesis, Cholesterol side-chain cleavage
enzyme, Steroidogenic acute regulatory protein (StAR), 17α-hydroxylase, 3β-hydroxysteroid dehydrogenase, Aromatase
Background
Polycystic ovary syndrome (PCOS) is one of the most
common endocrine disorders in reproductive-aged
women [1] causing hyperandrogenism (clinical and/or
biochemical), and oligo/anovulation [2, 3]. Hyperandro-
genism could be responsible for some of the clinical
features of PCOS such as hirsutism [4]. Although the
exact mechanism of hyperandrogenism in PCOS is not
clear, it is well known that ovaries of women with
PCOS have alterations in steroidogenesis at multiple
enzymatic levels [5]. Androgen production in women
normally occurs in the ovaries, adrenals, and peripheral
tissues such as adipose tissue and skin due to conversion
of androgen precursors [6, 7]. The ovaries and the adrenal
glands account for half of the androstenedione and T
production while adrenal glands account for the majority
of DHEAS [8, 9]. In PCOS, elevation in serum androgens
such as dehydroepiandrosterone (DHEA), DHEA sulfate
(DHEAS), androstenedione, and testosterone (T) is ob-
served due to abnormally increased ovarian and adrenal
production [10–15]. Elevation in androgen levels has been
reported in 60–80 %, while elevation in serum DHEAS
alone has been reported in approximately 20–30 % in
women with PCOS [8, 16]. This could be due to the
increased production and/or reduced clearance of an-
drogens in PCOS [17].
One of the molecules that are elevated in women
with PCOS is Advanced Glycation End Products (AGEs)
[18, 19]. AGEs, also called “glycotoxins,” are the bypro-
ducts of Maillard reaction in which the carbonyl group
of carbohydrates non-enzymatically interacts with lipids
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or with the amino group in proteins [20]. AGEs can be
formed endogenously by the body or absorbed exogen-
ously by intake of diet containing high levels of AGEs
(such as fast-food diet) or by smoking [21]. AGEs are
known to play a role in the pathogenesis of different
diseases such as diabetes, aging, Alzheimer disease,
atherosclerosis, renal disease, and recently PCOS by
causing oxidative stress, altering enzymatic activities,
affecting cytotoxic pathways, or damaging nucleic acids
[19, 22, 23]. AGEs can exert their effect via receptor-
independent pathway (for example by binding to the
extracellular matrix in many organs) or via receptor-
dependent pathway by interacting with their cellular
membrane receptor RAGE [24]. Another receptor
called soluble receptor for AGEs (sRAGE) circulates
throughout the body and is considered a decoy because
it binds AGEs and prevents their binding to RAGE thus
attenuating their inflammatory effects on bodily tissues
[25, 26] (Fig. 1). Data have shown that serum levels of
AGEs and the expression of their proinflammatory
RAGE are elevated in the ovarian tissue of women with
PCOS, potentially altering steroidogenesis and folliculo-
genesis [27, 28]. The purpose of this review is to
summarize the alterations in steroidogenesis that occur
in women with PCOS at the level of several enzymes in
granulosa and theca cells, and to present data in sup-
port of the hypothesis that elevations in systemic AGEs
could be partly responsible for PCOS-related alter-
ations in steroidogenesis.
Material and methods
Data extraction, inclusion criteria, search strategy, and
outcome measures
A systematic review of basic science (in vitro and in
vivo) and clinical studies (retrospective and prospect-
ive) available in PubMed through June 2016 was con-
ducted. We used the following search terms: “PCOS,”
“steroidogenesis,” “enzyme,” “hyperandrogenism,” “hor-
mone,” “AGEs,” “RAGE,” and “soluble receptor for
AGEs (sRAGE), cholesterol side-chain cleavage enzyme
cytochrome P450 (CYP11A1 or P450scc), steroidogenic
acute regulatory protein (StAR), 17α-hydroxylase
(CYP17A1), 3β-hydroxysteroid dehydrogenase (3β-HSD),
and aromatase.” The references from the related manu-
scripts were reviewed. All the abstracts of citations from
relevant articles were checked. The reviewers considered
the abstracts and full text articles from the citations if they
were found potentially relevant to steroidogenesis and
PCOS. Data extraction was done from the text, graphs,
and tables of the identified articles. Additional references
were searched from the reference list of the relevant
articles. Data abstraction was done and presented in a
systemic manner. The main outcomes included changes
in steroidogenic enzyme activity at the level of theca
and granulosa cells.
Results
Alteration in steroidogenesis in PCOS
The changes at the molecular level in granulosa and
theca cells of polycystic ovaries are poorly under-
stood. Women with PCOS generally have elevated
gonadotropin-releasing hormone (GnRH) pulsatile ac-
tivity, high levels of luteinizing hormone (LH), hyper-
activity of theca-stromal cell and altered activity of
granulosa cell that causes reduced production of estra-
diol (E2) and progesterone (P4) by pre-ovulatory follicle
[29, 30]. Sander et al. [31] reported lower levels of E2
and P4 in spite of hyper-luteinized milieu in the ovarian
follicles of women with PCOS. In the theca cells, it has
been proposed that there is an increased expression of
certain alleles that are responsible for the expression of
steroidogenic enzymes [32, 33].
Jakimiuket al [34] studied the genetic basis of recep-
tors in granulosa and theca cells of polycystic ovaries
and reported higher mRNA expression levels of LH
receptor (LHR), StAR, CYP11A1, and CYP17A1. Doldi
et al. [35] compared in vivo and in vitro E2 and P4 levels
in women with and without PCOS undergoing in vitro
fertilization (IVF) and demonstrated higher serum levels
of E2 and P4 (P < 0.01 and P < 0.05; respectively) in
women with PCOS on the day of human chorionic go-
nadotrophin (HCG) injection trigger. While, after HCG
stimulation, in vitro P4 level was increased in granulosa
cells of the control group in comparison to granulosa
Fig. 1 Schematic diagram of the pathogenetic effects of AGEs. AGEs
could damage cellular structures via formation of cross-links between
key molecules in the basement membrane of the extracellular matrix.
The interaction with the cell membrane receptor RAGE induces
intracellular inflammation and apoptosis. The circulating receptor
for AGEs (sRAGE) acts as decoy by binding the circulating AGEs,
thus conferring a potential protective role
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cells of the PCOS group; however, E2 levels were similar
in both groups. Additionally, Catteau-Jonard et al. [36]
showed dysregulation of granulosa cells in addition to
intrinsic dysfunction leading to hyperandrogenism and
increased expression of FSH receptor (FSHR) and
androgen receptor (AR) in stimulated ovaries of
women with PCOS. On the other hand, Almahbobi et
al. [37] studied the function of granulosa cells from
normal and polycystic ovaries and found that E2 pro-
duction in response to FSH stimulation in polycystic
ovaries was not different than normal ovaries suggest-
ing no intrinsic abnormalities of granulosa cells in the
polycystic ovaries.
The pathway of all steroid hormone synthesis begins
with the conversion of cholesterol to pregnenolone by
CYP11A1 [38, 39] (Fig. 2). Conversion of pregnenolone
to 17-hydroxypregnenolone and P4 to 17-
hydroxyprogesterone (17 OH-P) is mediated by
CYP17A1 which has dual functions of both 17 α-
hydroxylase and 17, 20-lyase [40]. Then, 17-
hydroxypregnenolone is converted into dehydroepian-
drosterone (DHEA) by the 17,20 lyase activity of the
same enzyme. DHEA is converted to androstenendione
by 3β-HSD enzyme [5]. Various studies have inspected
the activity of the enzymes involved in the biosynthesis
of steroid hormones in PCOS [41, 42] (Table 1). The
production of P4, 17 OH-P, DHEA, androstenedione,
and T increase in LH-stimulated theca cells in a dose-
dependent manner [43]. The following steroidogenic
enzymes will be discussed here in this manuscript:
P450scc (CYP11A1)
CYP11A1 regulates the first step of steroidogenesis and
forms pregnenolone from cholesterol [39]. In polycystic
ovaries, there seems to be an alteration in the CYP11A1
gene expression. For instance, Franks et al. [32] described
the role of CYP11A1 encoding gene in the pathogenesis of
excess androgen production in women with polycystic
ovaries. Their data from both association and linkage
studies suggested that CYP11A1 is a major genetic sus-
ceptibility locus for PCOS. They examined the segregation
of CYP11A1 in 20 families and performed association
studies in premenopausal women with polycystic ovaries
and matched control women from a similar ethnic
background. Using a microsatellite marker in the pro-
moter region of CYP11A1, they performed genotype
analysis after PCR amplification. Their results demon-
strated that differences in expression of CYP11A1
could account for variation in androgen production in
women who have polycystic ovaries. Using polymorphic
markers in the region of CYP11A1, they carried out
non-parametric linkage analysis and found evidence for
excess allele sharing at the CYP11A1 locus.
Ovarian theca cells isolated from PCOS follicles and
maintained in culture produce elevated levels of P4 and
androgen compared to theca cells of women without
PCOS [44]. Wickenheisser et al. [44] evaluated CYP11A1
gene at transcriptional and post-transcriptional level by
quantitative RT-PCR, promoter functional analyses, and
degradation studies of mRNA in theca cells of normal and
polycystic human ovaries placed in long-term culture. The
Fig. 2 Potential effect of AGE-RAGE binding on steroidogenic enzymes. The binding of AGEs to RAGE induces several steroidogenic enzymes
which might lead to increase in testosterone production. Green color represents induction. StAR: Steroidogenic Acute Regulatory protein, P450scc:
cholesterol side chain cleavage enzyme, CYP17A1: 17 alpha-hydroxylase and 17, 20 lyase, and 3β-HSD: 3β hydroxysteroid dehydrogenase
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Table 1 Changes in steroidogenesis observed in PCOS and PCOS models
Study Subjects, animals, or cell line Intervention/gene quantification Outcome
Li et al., 2013
[46]
- PCO-like hyper androgenic
rat (Sprague Dawley rat)
model induced by insulin
and hCG injections
- P450scc (CYP11A1) and CYP17A1 gene
expression in ovarian theca cells
- Ovarian morphology
- Changes in estrous cycle
- Ovarian androgen production
- Elevated expression of P450scc in thecal and
stromal cells
- Elevated CYP17A1 gene expression
- Reduced granulosa cell layers and augmented
theca cell layers with multiple large cysts
- Abnormal estrous cyclicity
- Elevated androstenedione and T levels
Franks et al.,
1997 [32]
- Symptomatic women with






symptoms) (n = 51)
- No PCOS with normal ovaries
on ultrasound (n = 59)
- Genotype analysis of CYP11A1 using
microsatellite marker in the promoter region
- Non-parametric linkage analysis in CYP11A1
region using polymorphic markers
- Excess allele sharing/linkage at the CYP11A1
locus with a non-parametric linkage score of
3.03 (probability of CYP11A1 gene being linked
to PCOS)
- CYP11A1 as a major genetic susceptibility locus
for PCOS
Wickenheisser
et al., 2012 [44]
- Women with PCOS (n = 5),
defined by NIH consensus
guidelines
- Women without PCOS (n = 5)
- CYP11A1 gene expression at transcriptional
and post-transcriptional level using RT-PCR,
mRNA degradation studies, and functional
promoter analyses
- Basal and cAMP-dependent CYP11A1
promoter function
- CYP11A1 mRNA half-life
- Expression of CYP17A1 gene
- Increased CYP11A1 promoter activity and steady
state CYP11A1 mRNA abundance in both basal
and forskolin stimulated conditions in PCOS
theca cells
- More than 2-fold increase in CYP11A1 mRNA
half-life
- Increased basal mRNA stability in PCOS ovarian
theca cells
- Increased expression of CYP17A1 gene at both
transcriptional and post-transcriptional level in
PCOS
Liu et al., 2011
[45]
- Women with PCOS (n = 12)
who underwent laparoscopic
ovarian wedge resection
- Control women (n = 12) who
underwent contralateral
ovarian biopsy
- Expression of CYP11A1 mRNA and protein
levels using RT-PCR and Western blot
analyses




- Women with (n = 28) PCOS
and without (n = 28) PCOS
who underwent IVF
- CYP11A1 mRNA expression levels in
luteinized granulosa cells
- Follicular fluid E2 and P4 levels
- StAR and 3β-HSD mRNA expression in
granulosa cells
- No change in CYP11A1 mRNA expression levels
in granulosa cells between two groups
- Significantly lower E2 and P4 levels in the
follicular fluid of women with PCOS
- Increased expression of StAR mRNA levels in
women with PCOS




- 11 months-old female
offspring of ewe PCO-model
induced by prenatal testos-
terone propionate (TP) (n = 9)
- Age-matched control ewe
(n = 5)
- StAR gene expression
- Androstenedione levels
- Enhanced androstenedione secretion in the antral
follicles of PCO-like ewe that was augmented after
treatment with recombinant LH
- Higher thecal LH receptor gene expression
- Increased number of estrogenic follicles




- Women with PCOS (n = 12)
undergoing
electrocauterization of the
ovarian surface or wedge
resection of the ovaries,






- Expression of StAR, CYP17A1, CYP11A1 and
LH receptor mRNA
- Elevated expression of StAR, CYP17A1, CYP11A1,
and LH receptor mRNA in the theca cells of
women with PCOS
- Increased LH receptor and CYP11A1 expression in
granulosa cells of women with PCOS
Kahsar-Miller et
al., 2001 [50]
- Women with PCOS (n = 7)
- Control women (n = 10)
- StAR expression
- Ovarian morphology
- Significantly higher number of follicular cysts and
staining for StAR immunoreactivity in theca cell
of women with PCOS
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investigators demonstrated that basal and forskolin-
stimulated steady state CYP11A1 mRNA abundance and
CYP11A1 promoter activities were significantly increased
in PCOS theca cells (Table 1). They also showed that
CYP11A1 mRNA half-life increased more than two-folds
in PCOS theca cells. These data suggest that elevated
CYP11A1 mRNA abundance in PCOS cells results from
increased transactivation of the CYP11A1 promoter and
increased CYP11A1 mRNA stability. Similarly using RT-
PCR, Western blot, and immunohistochemistry, Liu et al.
[45] examined the expression of CYP11A1 in follicles in
their early and late stages of development in women with
and without PCOS who underwent laparoscopic ovarian
wedge resection. They reported higher CYP11A1 mRNA
and protein levels in early-stage follicles of women with
PCOS. These changes could be in part responsible for the
changes observed in follicular development in polycystic
ovaries. In Sprague Dawley rat model, Li et al. [46] used a
hyperandrogenic PCO-like induced by insulin and HCG
injections to investigate changes in ovarian CYP11A1
expression (Table 1). Using Western blot and immuno-
histochemistry, they reported increased expression of
CYP11A1 in theca cells as well as abnormal estrous
cyclicity, increased ovarian weight/body weight ratio,
elevated ovarian androgen production (androstenedione
and T) with reduced number of granulosa cell layers and
increased number of theca cell layers compared to the
control rats [46]. One of the drawbacks of that study is
that insulin and HCG trigger a PCO-like phenotype that
is not similar to PCOS phenotype in humans.
Table 1 Changes in steroidogenesis observed in PCOS and PCOS models (Continued)
Nelson et al.,
1999 [51]
- Normal and PCOS theca
interna cells
- CYP17A1, CYP11A1, and 3β-HSD mRNA and
protein levels
- P4, 17OHP, and T levels
- Increased production of P4, 17OHP, and T by
theca cells of women with PCOS
- Elevated CYP17A1, CYP11A1, and 3β-HSD mRNA
and protein levels in theca cells of women with
PCOS
- No difference in StAR mRNA expression
Wickenheisser
et al., 2000 [55]
- Theca cells of women with
or without PCOS
- CYP17A1 and StAR promoter activity In PCOS theca cells:
- Four-fold greater CYP17A1 promoter activity
- Augmented basal and cAMP-dependent
CYP17A1 gene expression
- Slower degradation of CYP17A1 mRNA
- No change in StAR promoter activity
Doldi et al.,
2000 [57]
- Women with (n = 10) and
without (n = 10) PCOS
- 3β-HSD mRNA expression - Lower expression of 3β-HSD mRNA in PCOS
granulosa cells obtained from follicles
measuring≤ 10 mm and > 16 mm
Erickson et al.,
1979 [70]
- Granulosa cells from normal
and polycystic ovaries
- Ability of granulosa cells to aromatize
androgens after in vitro incubation of
granulosa cells with androstenedione, FSH
and LH
- Elevated E2 production in granulosa cells from
normal (8–15 mm) follicles
- Negligible E2 production by granulosa cells from
small (4–6 mm) follicles of both normal and
polycystic ovaries
- 17–24 fold increase in E2 production in PCOS
and control ovaries in response to FSH




- Granulosa luteal cells from
polycystic and normal ovaries
- Effect of atamestane (aromatase inhibitor) on
granulosa luteal cells
- Robust inhibition of basal aromatase activity after
treatment with atamestane in both groups with
more pronounced effect in cells of normal
ovaries in comparison to cells of PCOS ovaries
Andreani et al.,
1994 [71]
- Granulosa cells from
polycystic ovaries and normal
ovaries in the preovulatory
phase after oocyte retrieval
during GIFT
- E2 and P4 production in the presence or
absence of FSH
- 2–3 fold increase in E2 production in PCOS
ovaries after FSH treatment
- No change in P4 production after FSH treatment
Mason et al.,
1994 [65]
- Granulosa cells from normal,
ovulatory and anovulatory
polycystic ovaries
- FSH-induced E2 production
- Follicular androstenedione levels
- Significantly higher androstenedione in small
follicles (5–11 mm) from ovulatory PCOS




- Women with PCOS (n = 25),
- Women without PCOS
(n = 50)
- PCR analysis of genomic DNA and complete
sequence of all exons of the aromatase gene
and its promoter
- Mutations of the P450arom gene or its promoter
were not found to be associated with PCOS
Abbreviations: PCOS polycystic ovary syndrome, FSH Follicle-stimulating hormone, LH luteinizing hormone, P450scc cholesterol side-chain cleavage enzyme, StAR
steroidogenic acute regulatory protein, 3β-HSD 3beta-hydroxysteroid dehydrogenase, CYP17A1 17α-hydroxylase, hCG human chorionic gonadotropin, T testosterone,
IVF in vitro fertilization, GIFT gamete intra-fallopian transfer, E2 estradiol, P4 progesterone, RT-PCR reverse transcription-polymerase chain reaction,
17OHP 17-hydroxyprogesterone
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One the other hand, not all studies has shown upregula-
tion in CYP11A1 (Table 1). For instance, Sander et al. [31]
compared CYP11A1 mRNA expression levels in granulosa
cells extracted from women with or without PCOS who
underwent controlled ovarian hyperstimulation for IVF
and reported no changes between both groups of women.
They reported that women with PCOS had significantly
lower E2 and P4 levels in their follicular fluid. One draw-
back of that study is that it evaluated mRNA levels in
luteinized granulosa cells that were exposed to high doses
of gonadotropins. Additionally, CYP11A1 mRNA levels
were not measured in theca cells.
StAR
StAR protein helps in the transport of cholesterol from
the cell membrane into the mitochondria leading to the
initiation of the steroidogenic pathway [47, 48]. Sander
et al. [31] reported an increased expression of StAR
mRNA levels in granulosa cells collected from women
with PCOS who underwent controlled ovarian hyper-
stimulation for IVF compared to women without PCOS.
Hogg et al. [49] conducted a study on ewe PCO-model
induced by prenatal T propionate (TP) administration to
pregnant ewe. The offspring females were sacrificed at
11 months of age after synchronization of the estrous
cycles by administration of prostaglandin to ensure that
they were in the follicular phase. Their ovaries were
assessed for steroidogenic gene expression. Both in vivo
and in vitro, enhanced androstenedione secretion was
observed in the antral follicles of TP-treated PCO-like
ewe, more so after treatment with recombinant LH.
Augmented thecal LHR gene expression was also present
in these animals. Additionally, there was up-regulation in
StAR (P < 0.01), CYP11A1 (P < 0.05), CYP17A1 (P < 0.05),
and 3β-HSD (P < 0.01) mRNA expression levels in theca
cells. This indicates that the ovarian programming
induced by prenatal androgens in animals could cause
hypersecretion of androgens by altering LH sensitivity
and up-regulation of steroidogenic genes in theca cells.
Jakimiuk et al. [34] investigated the gene expression of
steroidogenic enzymes including StAR from granulosa
and theca cells of women with PCOS (n = 12) under age
44 years undergoing electrocauterization of the ovarian
surface or wedge resection of their ovaries for infertility
treatment and control (n = 24). Participants in both
groups were age-matched premenopausal women under-
going total abdominal hysterectomy with bilateral oo-
phorectomy for non-ovarian indications. Granulosa cells
were obtained from both the follicular fluid (after centri-
fugation) and the wall of the follicles (by scraping).
Theca cells were collected from the follicle after micro-
dissection. That study showed that in theca cells, expres-
sion of StAR, CYP17A1, CYP11A1 and LHR mRNA
were significantly higher in PCOS follicles in comparison
to the size-matched control follicles. This indicates that
theca cells in PCOS are hyperstimulated thus they pro-
duce excessive amounts of androgens. That study also
showed that in granulosa cells, LHR and CYP11A, but
not StAR, mRNA expression was higher in PCOS than
in control follicles indicating that granulosa cells in
PCOS have increased LH responsiveness that may con-
tribute to arrested follicle development.
On the other hand, some studies showed no changes
in StAR expression in PCOS women. For instance, the
distribution of StAR in theca cells of women with PCOS
(n = 7) and healthy females (n = 10) was studied by
Kahsar-Miller et al. [50]. They assessed StAR expression
by immunohistochemistry and Western blot in polycys-
tic and normal ovaries. Although they reported signifi-
cantly greater number of follicular cysts with theca cell
staining for StAR immunoreactivity in women with
PCOS, the distribution of StAR immunoreactivity within
most of the ovarian structures (including granulosa and
theca cells) was not different in the ovaries of women
with PCOS compared to ovaries of healthy women. An-
other study conducted by Nelson et al. [51] evaluated
the steroidogenesis in human theca interna cells stripped
from ovarian follicle walls of women who underwent
hysterectomy. They demonstrated that increased pro-
duction of P4, 17-OHP, and T by PCOS theca cells prop-
agated in long-term culture (with or without forskolin)
was due to increased mRNA and protein activity of
CYP17A1, CYP11A1, and 3β-HSD but not StAR enzyme
(Table 1). This indicates that the intrinsic defect in the
steroid biosynthesis in theca cells at genetic level is not
due to overall differences in the regulation of cAMP or
adenylate cyclase (activated by forskolin) but due to se-
lective alterations in steroidogenic enzyme expression.
CYP17A1
CYP17A1 is an enzyme that belongs to cytochrome
P450 superfamily. It catalyzes the activities of both 17 α-
hydroxylase and 17, 20 lyase [52]. CYP17A1 is elevated
in the ovaries of women with PCOS, which is partly re-
sponsible for the altered steroidogenesis in these women
[51, 53]. As mentioned earlier (under StAR section),
Nelson et al. [51] demonstrated that CYP17A1 enzyme
expression and activity is elevated in the human theca
interna in culture. As mentioned earlier (under CYP11A1
section), Li et al. [46] demonstrated in a hyperandrogenic
PCO-like rat model induced by insulin and HCG injec-
tions that the expression of CYP17A1 gene was signifi-
cantly higher in theca cells compared to control rats.
Wickenheisser et al. [54] (details on the study are de-
scribed above, under CYP11A1 section) demonstrated
increased expression of CYP17A1 gene at both tran-
scriptional and post-transcriptional level in theca interna
cells of human polycystic ovaries. In another experiment,
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Wickenheisser et al. [55] in transfected theca cells with a
series of CYP17A1 reporter constructs and showed that
cotransfection of steroidogenic factor-1 (SF-1) was re-
quired for the detection of both basal and stimulated
promoter CYP17A1 activity. Additionally, there was a 4-
folds greater CYP17A1 promoter activity in PCOS theca
cells compared to normal theca cells. PCOS theca cells
had augmented basal and cAMP-dependent CYP17A1
gene expression and there was slower degradation of
CYP17A1 mRNA (Table 1). These data suggest that
dysregulation of the processes involved in CYP17A1
transcription in PCOS theca cells may, in part, account
for the increased ovarian androgen production.
3β-HSD
3β-HSD is an enzyme that catalyzes the conversion of
pregnenolone to P4, the conversion of 17-
hydroxypregnenolone to 17-OHP, and the conversion
of DHEA to androstenedione. It belongs to the family
of oxidoreductase and exists as two isozymes: 3β-HSD I
and II [56]. Isozyme II exists in the ovary and the ad-
renal glands and it contributes to androgen biosyn-
thesis. Evidence showed conflicting results related to
3β-HSDII activity in polycystic ovaries with increase,
decrease, or no change in its mRNA expression and en-
zymatic activity [31, 51, 57].
Nelson et al. [51] (details are provided under StAR
section above) showed elevated 3β-HSD activity per
theca cell under both basal and forskolin-stimulated
conditions. Doldi et al. [57] evaluated 3β-HSD mRNA
expression using RT-PCR in luteinizing granulosa cells
from follicles of women with PCOS. They reported lower
expression of this enzyme in the PCOS granulosa cells ob-
tained from follicles measuring ≤ 10 mm and > 16 mm in
comparison to control normal granulosa cells. Their data
demonstrated that downregulation of 3β-HSD gene could
be responsible for the reduction in P4 synthesis by PCOS
granulosa cells. In contrast, Sander et al. [31] reported no
change in 3β-HSD mRNA expression in polycystic ovaries.
Accumulating evidence suggest the basis of elevated an-
drogens in polycystic ovaries could be due to influence
at genetic level involving genes of multiple enzymes and
subsequently modification in the signal transduction
pathways that regulate steroidogenesis [58].
CYP19A1
Aromatase, encoded by CYP19A1 gene, is a microsomal
enzymatic complex that catalyzes the formation of estro-
gens (estrone and E2) from androgens (androstenedione
and T) during steroidogenesis [59]. LH stimulates ste-
roidogenesis by producing androgens from theca interna
cells, which are converted to E2 in granulosa cells by
aromatase enzyme under FSH stimulation [60]. Down-
regulation of this enzyme has been reported to be
partially responsible for the altered steroidogenesis in
PCOS [61–63] although some data reported elevated
aromatase levels in polycystic ovaries [64, 65].
Understanding granulosa cell aromatase and E2 pro-
duction in the non-PCOS state is crucial in elucidating
changes in aromatase activity and E2 production in
PCOS. Foldesi et al. [66] demonstrated in vitro the ability
of granulosa-lutein cells to have aromatase activity and
the ability of these cells to produce E2 spontaneously
without the support of androgens and gonadotropins. The
addition of recombinant human FSH (rFSH) to granulosa-
lutein cells in culture resulted in increased production of
E2 in a dose- and time-dependent manner even in the ab-
sence of exogenous androgens. Addition of T caused sub-
stantial increase in the basal production of E2 that can be
moderated by certain follicular fluid compounds [67, 68].
Origin of the follicular fluid and the size of the follicles
might decide the stimulatory or inhibitory action on
ovarian E2 production by aromatase [69]. Guet et al.
[61] investigated in vitro the role of human dominant
follicular fluid in altering aromatase activity. They col-
lected follicular fluid by laparoscopy from the dominant
follicle of the ovaries of women with tubal or unex-
plained infertility before their LH surge. Granulosa cells
were collected from the women undergoing IVF. They
measured aromatase activity after adding various con-
centration of follicular fluid and control serum (2.5, 5,
10 and 20 %) to granulosa cells and reported reduced
aromatase activity with addition of higher concentra-
tion of follicular fluid [61]. This indicates that follicular
fluid of dominant follicles contains factors that inhibit
aromatase activity of these cells.
Erickson et al. [70] studied both in vivo and in vitro
granulosa cell ability of synthesizing E2 in normal and
polycystic ovaries. They incubated granulosa cells from
both normal and polycystic ovaries with androstene-
dione and measured E2 concentration. They found neg-
ligible amounts of E2 production by granulosa cells of
small follicles (4–6 mm) from both PCOS and control
ovaries. However after culture of both PCOS and control
granulosa cells with FSH (100 ng/mL) or LH (100 ng/
mL) for 48 h, 24 and 17 times increase in E2 production
was noted in response to FSH in both groups respect-
ively with slight or no effect of LH. They also reported
elevated E2 production in granulosa cells obtained from
granulosa cells of follicles measuring 8–15 mm in the
control group. They suggested that granulosa cells from
polycystic ovaries have a natural aromatase activity in
response to FSH but their follicles never develop to the
size (8–15 mm) at which they start producing E2, causing
a decline in E2 production in PCOS.
In contrast, Pierro et al. [64] described evidence of an
exaggerated in vitro activity of aromatase in granulosa
cells of PCOS. They studied the effect of a competitive
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aromatase inhibitor, atamestane, on granulosa luteal cells
obtained from women with or without PCOS following
controlled ovarian hyperstimulation. They reported
marked inhibition of aromatase activity in granulosa
cells from normal ovary in comparison to granulosa cells
from polycystic ovaries with lower minimal effective
dose of the inhibitor and higher inhibitory effect in
normal ovaries suggesting that there was a higher basal
aromatase activity in PCOS. Another study demon-
strated that aromatase is more sensitive and responsive
to FSH in granulosa luteal cells of polycystic ovaries in
comparison to normal ovaries [71]. Similar findings
were confirmed by Mason et al. [65] who described an
enhanced aromatase activity in granulosa cells of poly-
cystic ovaries. They evaluated FSH-induced E2 produc-
tion in granulosa cells in normal and ovulatory or
anovulatory polycystic ovaries. There were no signifi-
cant differences in FSH or E2 in follicular fluid, but
significantly higher androstenedione in small follicles (5
to 11 mm) from ovulatory PCOS compared to normal
women. Also, there was 6–10 times more FSH-induced
E2 response in anovulatory PCOS compared to con-
trols. Söderlund et al., [72] investigated genomic DNA
after PCR analysis from follicles of polycystic ovaries
and found that CYP19A1 gene or its promotor muta-
tion was not associated with reduced activity of aroma-
tase in polycystic ovaries (Table 1).
Role of AGEs in altering steroidogenesis in PCOS
A possible role of AGEs in altering steroidogenesis in
PCOS, directly or indirectly, is still unclear and under
investigation (Fig. 3). A recent study showed that AGEs
such as toxic AGE (TAGE), pentosidine and carboxy-
methyl lysine (CML) in follicular fluid and serum TAGE
(S-TAGE) correlated negatively with E2 levels (follicular
fluid pentosidine, r = -0.29, p < 0.001; follicular fluid CML,
r = -0.31, p < 0.0001; follicular fluid TAGE, r = -0.26, p <
0.01; and S-TAGE, r = -0.25, p < 0.01) in PCOS patients
undergoing assisted reproductive technology [73]. On
immunohistochemical localization of normal and PCOS
ovaries, staining for AGEs was highest in endothelial cells
and granulosa cell layer of PCOS ovaries [74].
The abnormal steroidogenesis in PCOS could lead to
elevated androgen synthesis and abnormal follicular
development [75]. AGEs are associated with hyperandro-
genemia in PCOS (Fig. 1, Fig. 2, and Table 2). Diamanti-
Kandarakis et al. [27] investigated serum AGEs levels
and RAGE expression in monocytes of PCOS (n = 29)
and control (n = 22) group and their correlation with T
levels. They demonstrated higher serum AGEs protein
levels (U/mL) (mean ± SE: 9.81 ± 0.16 vs. 5.11 ± 0.16, P <
0.0001), and elevated expression of RAGE (% + ve)
(mean ± SE: 30.91 ± 10.11 vs. 7.97 ± 2.61, P < 0.02) in
patients with PCOS compared to control group. In
addition, a positive correlation was observed between
serum AGEs and T (r = 0.73, P < 0.0001), even after
controlling for BMI (partial correlation coefficient = 0.61,
P = 0.0001). In another study, the same authors fed Wistar
rats diet containing high (H-AGE) or low (L-AGE) AGEs
for 6 months. In H-AGE rats, they found elevated AGE
deposition in ovarian theca interna cells (P = 0.003), in-
creased RAGE staining in granulosa cells (P = 0.038), and
higher plasma T (P < 0.001) compared to L-AGE rats [76].
In addition, Tantalaki et al. [77] investigated the role of
AGEs dietary intake on hormonal status of women with
PCOS. They gave women with PCOS (n = 23) isocaloric
diet containing H-AGE or L-AGE for 2 months and found
higher serum AGEs (IU/mL) (mean value ± SD: 10.4 ± 1.4
vs 8.2 ± 1.6, P < 0.05) along with elevated T, free androgen
index (FAI) and androstendione levels (T: 1.04 ± 0.43
(ng/ml) vs 0.77 ± 0.32 (ng/ml), FAI: 15.4 ± 16 vs 11.1 ±
10.7, androstendione: 3.76 ± 1.10 (ng/ml) vs 3.37 ± 0.96
(ng/ml), P < 0.05) in PCOS patients with H-AGE diet
compared to L-AGE diet. Chatzigeorgiou A et al. [78]
fed female Wistar rats H-AGE or L-AGE diet for
3 months and demonstrated elevated levels of plasma T
in rats in the H-AGE diet group. Additionally, lower
levels of E2 and P4, higher levels of T along with de-
creased expression of scavenger receptors of AGEs were
found in H-AGE diet fed rats compared to L-AGE diet
fed animals [78]. These studies substantiate the associ-
ation between AGEs and hyperandrogenism in PCOS.
Accumulating evidence has demonstrated that dietary
modification with intake of diet containing low AGEs
Fig. 3 Relationship between AGEs and hyperandrogenism in PCOS.
The elevation in serum AGEs and the overexpression of ovarian
RAGE in PCOS are associated with hyperandrogenism. AGEs,
advanced glycation end products; RAGE, receptor for advanced
glycation end products
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can reduce the concentration of plasma bioavailable
testosterone and can modify PCOS phenotypes [21, 79].
Obesity and insulin resistance are commonly observed
in women with PCOS [1]. Recent studies have demon-
strated a role for AGEs in the development of obesity
[80, 81]. For example in one study, after feeding C57/
BL6 and db/db mice with H-AGE or L-AGE diet for
6 months, a significant weight gain was observed in H-
AGE diet group [80]. In another study, when C57BL6
mice were fed diet with or without AGEs, increased
adiposity was noted in animals fed diet-containing AGEs
[81]. Insulin resistant women with PCOS without hyper-
glycemia have elevated serum levels of AGEs and upregu-
lation in RAGE expression in their circulating monocytes
[27]. Additionally, serum AGE levels are positively
correlated with testosterone level, free androgen index,
insulin, HOMA and waist-to-hip ratio in women with
PCOS who did not have hyperglycemia [82]. Another
study has shown that increased serum AGE levels is
observed in non-insulin resistant lean women with
PCOS suggesting that this association is independent
on insulin resistance state [28].
The AGE-RAGE interaction leads to downstream sig-
naling cascades that play important role in the RAGE
mediated actions of AGEs [83]. Mechanism of AGE-
RAGE signaling in altering steroidogenesis in PCOS has
been studied by Diamanti-Kandarakis et al. [84] in human
ovarian granulosa cells (KGN) in which they cultured
KGN granulosa cell line with LH alone and LH along with
human glycated albumin (HGA, representative of AGEs)
for 0–2 h. They hypothesized that the interference of
ERK1/2 activation by AGE-RAGE signaling in human
granulosa cells causes attenuation of LH action. The basis
of this hypothesis was the involvement and activation
of ERK1/2 by both AGE-RAGE intracellular signaling
and LH-induced oocyte maturation and ovulation. In
Table 2 Studies evaluating the association between AGEs and PCOS




- Female Wistar rats fed high (H-AGE) or
low (L-AGE) diet for 6 months
- AGEs’ levels in ovarian theca cells
- RAGE expression
- Plasma T level
In H-AGE diet rats:
- Elevated AGEs’ deposition in ovarian theca
interna cells
- Increased RAGE staining in granulosa cells
- Higher plasma T levels
Chatzigeorgiou
A et al., 2013
[78]
- Female Wistar rats fed high (H-AGE) or
low (L-AGE) diet for 3 months
- Plasma T, E2 and P4 levels
- Expression of scavenger receptors for
AGEs
In H-AGE diet rats:
- High T plasma levels
- Lower levels of E2 and P4




- Women with (n = 71) and without
(n = 86) PCOS undergoing ART
- Measurement of toxic AGEs (TAGE),
pentosidine, and CML in blood and
follicular fluid
- Negative correlation between E2 and
follicular fluid AGEs (TAGE, Pentosidine
and CML)





- Women with (n = 29) or without
(n = 22) PCOS
- Serum AGEs’ levels and RAGE expression
in circulating monocytes - Correlation
between AGEs and T levels
- Higher serum AGEs’ levels and elevated
expression of RAGE in PCOS




- Women with PCOS (n = 23) were
given isocaloric diet containing high
(H-AGE) or low (L-AGE) levels of AGEs
for 2 months
- Serum AGEs and androgens (T, and
androstendione) levels, free androgen
index
Women with PCOS on H-AGE diet:
- Higher serum AGEs





- Human ovarian granulosa cell line
(KGN) treated with recombinant LH in
the presence or absence of human
glycated albumin (HGA)
(representative of AGEs)
- Effect of AGE-RAGE on LH signaling - Interference of LH actions by ovarian AGEs
due to sustained activation of ERK1/2 and
MAPK signaling




- Cumulus granulosa cells (CCs) (n = 6)
treated with HGA (representative of
AGEs) obtained from women who
underwent IVF
- KGN granulosa cell line treated with
recombinant AMH (rAMH) in the
presence or absence of HGA
- Follicular fluid levels of sRAGE and
AGEs in women undergoing IVF
- mRNA expression of LH receptor (LHR),
AMH, AMHR-II, and RAGE by RT-PCR
- RAGE protein expression by
immunofluorescence
- Immunofluorescence for SMAD 1/5/8
phosphorylation (AMH signaling pathway)
- Correlation between sRAGE and AGEs
(pentosidine and CML) in follicular fluid
- HGA increased LHR and AMHR-II mRNA
levels
- HGA did not change AMH mRNA levels
- HGA increased RAGE protein levels
- HGA significantly increased rAMH-induced
SMAD 1/5/8 phosphorylation
- sRAGE positively correlated with
pentosidine and CML
Abbreviations: AGEs advanced glycation end Products, RAGE receptors for advanced glycation end products, ART Assisted Reproductive Technology, CML
carboxymethyl lysine, E2 Estradiol, T testosterone, AMH anti-Mullerian hormone, AMHR-II AMH receptor, sRAGE soluble receptor for AGEs, IVF in vitro fertilization
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granulosa cells LH-induced oocyte maturation and ovu-
lation requires activation of MAPK specifically ERK1/2
pathway [85, 86]. The authors showed that AGEs cause
inappropriate activation of ERK1/2 pathway in KGN
granulosa cells that could lead to altered steroidogenesis
these cells (Fig. 4).
RAGE is a multi-ligand receptor that belongs to the
immunoglobulin superfamily. RAGE ligands include
AGEs, high mobility group box 1 (HMGB1), S100/cal-
granulins, Mac-1, phosphatidylserine and amyloid β (Aβ)
[87–89]. RAGE acts as an extracellular S100 receptor due
to sharing of same structural features with S100/calgra-
nulin [90]. Another proinflammatory multifunctional
protein called HMGB1 binds RAGE and acts as a tran-
scriptional regulator for inflammatory response and
tumor progression [91–93]. The function of HMGB1 is
dependent on its location (i.e., intracellular or extracllular).
Intracellular HMGB1 acts as a regulator of transcription
by binding to DNA. HMGB1 can be either actively
secreted by the cell or passively released by the cell upon
its death [91]. Extracellular HMGB1 activates RAGE,
which in turn can promote an immune response [94, 95].
Recently, p38-regulated/activated protein kinase (PRAK)
has been identified as a novel RAGE ligand [87]. Further
studies are required to investigate the better understand-
ing of the involvement of RAGE and its interaction to
different ligands in the pathogenesis of PCOS.
Merhi et al. [96] recently studied the adverse effects of
AGEs on steroidogenesis and follicular development. The
authors measured sRAGE, AGEs (pentosidine and CML)
by ELISA in follicular fluid of women who underwent IVF
and found positive correlation of sRAGE with pentosidine
(r= 0.24), and CML (r = 0.32) (p < 0.05). They measured
mRNA for LHR, AMH and its receptor (AMHR-II), and
RAGE after culture of cumulus granulosa cells of women
who underwent IVF with media ± human glycated albumin
(representative of AGEs) for 48 h. They found 59 % increase
in LHR, and 52 % increase in AMHR-II mRNA levels (p <
0.05) with no change in AMHmRNA levels in HGA treated
granulosa cells compared to control (cells treated with
media alone). Finally, the authors treated KGN granulosa
cell line with recombinant AMH (rAMH; 50 ng/mL) with
or without HGA (0.4 ng/mL) and assessed SMAD 1/5/8
phosphorylation (AMH signaling pathway). Recombinant
AMH markedly increased the phosphorylation of SMAD 1/
5/8 in KGN cells compared to control cells. When KGN
cells were pretreated with HGA in the presence of rAMH,
the accumulation of phospho-SMAD 1/5/8 in the nucleus
was significantly augmented compared to control cells
(media alone) and compared to cells treated with rAMH
alone. These findings are in alignment to the above changes
described in various enzymes involved in steroidogenesis in
PCOS and further confirm the role of AGEs in alteration of
genes involved in steroidogenesis in PCOS [96].
Fig. 4 A diagram of pathways by which AGEs affect genes involved in steroid synthesis and follicular development. AGEs induce LHR mRNA
expression and alter LH hormone action by inappropriate activation of ERK1/2 pathway. The interaction of AGEs with its cell membrane receptor
RAGE induces StAR (Steroidogenic Acute Regulatory protein), P450scc (cholesterol side chain cleavage enzyme), CYP17A1 (17 alpha-hydroxylase
and 17, 20 lyase), and 3β-HSD (3β hydroxysteroid dehydrogenase) mRNA expression levels. AGE-RAGE interaction also induces AMHR-II mRNA
levels and increases SMAD 1/5/8 phosphorylation (AMH pathway). AGEs: advanced glycation end-products; RAGE: receptor for advanced glycation
end-products; AMH: anti-Mullerian hormone
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Conclusion
PCOS is a state of elevated androgen production, which
is caused by alteration in the steroid biosynthesis by
affecting different steroidogenic enzymes. Hyperandro-
genism is one of the causes of subfertility associated
with PCOS. Accumulating evidence has suggested the
possibility of underlying role of AGEs in altering steroid
bio-synthesis in polycystic ovaries by affecting enzyme
function/activity. AGE-induced augmentation of insulin
resistance and induction of inflammatory changes in
polycystic ovaries are other possible mechanisms that
contribute to altered steroidogenesis in polycystic ovaries.
If exact mechanism of AGEs induced hyperandrogenism
in PCOS is established, the targeted therapy against AGEs
will be beneficial to improve the reproductive outcome in
this patient population. In summary, AGEs seem to affect
ovarian steroid production. Understanding the role of the
AGE-RAGE/sRAGE axis in ovarian dysfunction, particu-
larly in women with PCOS who have elevated levels of
these AGEs, might shed light for better understanding
the mechanisms behind female reproduction.
Abbreviations
17 OH-P: 17- hydroxyprogesterone; 3β-HSD: 3β-hydroxysteroid
dehydrogenase; AGEs: Advanced Glycation End Products; AMH: Anti-
Mullerian hormone; AR: Androgen receptor; ART: Assisted reproductive
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DHEA: Dehydroepiandrosterone; E2: Estradiol; FSH: Follicle-Stimulating
Hormone; FSHR: FSH receptor; GnRH: Gonadotropin-releasing hormone;
HCG: Human chorionic gonadotrophin; IVF: In vitro fertilization;
LH: Luteinizing hormone; LH: Luteinizing hormone; P4: Progesterone;
P450scc: Cholesterol side-chain cleavage cytochrome P450; PCOS:
Polycystic ovary syndrome; RAGE: Receptors for AGEs; rAMH: Recombinant
AMH; rFSH: Recombinant human FSH; sRAGE: Soluble receptor for AGEs;
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